

# IMPLEMENTATION OF A MULTIDISCIPLINARY PERSONALISED MEDICINE UNIT FOR PHARMACOGENETIC TESTING

Fernández-Fradejas J<sup>1</sup>, Morín-Rodríguez M<sup>2</sup>, Delgado-Silveira E<sup>1</sup>, Moreno-Pelayo MÁ<sup>2</sup>, Álvarez-Díaz AM<sup>1</sup>

<sup>1</sup> Pharmacy Department. Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)

<sup>2</sup> Genetics Department. Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)

## What was done?


We have implemented a multidisciplinary Personalised Medicine Unit (PMU) at a third level hospital to facilitate preemptive pharmacogenetic (PGx) testing.

## Why was it done?

- There is an increasing number of gene-drug interactions with the potential to predict patient response to drugs.
- Although the study of genetic variants can be useful to achieve a safer and more effective pharmacotherapy, integration of personalised medicine in clinical practice has been challenging, mainly due to prescriber's scepticism and lack of clinical guidelines.

## How was it done?

The PMU provides its service with the involvement of Pharmacy and Genetics Department.



PGx report contains:

- Molecular information and its interpretation.
- Clinical pharmacotherapeutic recommendation according to the results obtained.


Dose adjustment recommendations follow CPIC and DPWG guidelines.



## What has been achieved?

- Three hundred and seventy patients have benefited from PGx testing.
- Mean turnaround time <10 days preventing treatment delays.
- Pharmacotherapeutic recommendations had an acceptance rate of 100%.

We have implemented seven gene-drug interactions



## What next?

Our next challenges are:

- Introducing next-generation sequencing for the study of new gene-drug interactions in the unit portfolio.
- Achieve a deeper integration of PGx information and clinical-decision support systems.

